Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Diversified Return International Eqty ETF vs Repligen Corporation Common Stock — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73 (market cap $382.97M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 29.1× JPMorgan Diversified Return International Eqty ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, JPMorgan Diversified Return International Eqty ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 121 Days and Repligen Corporation Common Stock for 0 Days on average.
| JPIN | RGEN | |
|---|---|---|
Market Cap | $382.97M | $11.14B |
Volume | 1,797 | 1,259,263 |
52-Week High | $77.80 | $194.57 |
52-Week Low | $65.86 | $102.87 |
Typical Hold Time | 121 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $73.52, up 0.65% today. Technical indicators are overwhelmingly bearish, with moving averages and oscillators signaling selling pressure, though the RSI suggests potential oversold conditions. The ETF provides broad exposure to international large-cap value stocks. A dividend of $0.51 is scheduled for payment in September 2026.
The outlook is cautious due to strong bearish technical signals. The primary opportunity lies in the ETF's international diversification and value focus, but risks include global market volatility and the current negative momentum. Investors should weigh the oversold RSI against the dominant sell signals.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
